L’Oréal patents methods for the prognosis, diagnosis and treatment of hair loss for alopecia

Write in his international patent, L’Oréal declared that it had developed a method for in vitroprognosis and / or diagnosis of “Common alopecic condition of the scalp”By measuring the level of expression of very specific genes * involved in the intercellular junctions of the scalp and / or the hair follicle. He also sketched a in vitromethod for evaluating the effectiveness of the treatment of a common alopecic condition, in particular by testing cosmetic treatments such as hair lotions, gels, shampoos and conditioners made using genetic modulators and certain active compounds.

* Genes identified by L’Oréal: CDH1, ACTB, ACTBL2, TUBB, TUBB2A, GSN, MY03B, MY05B, MY06, DSG2, DSG3, DSG4, DSC2, GJB2, GJA1, GJB6, GJA3, TJP2, CLDN819, CLDN10 and possibly CTNNB1 and CTNND2

L’Oréal said the prognosis, diagnosis and methods of treatment were specifically related to common alopecia caused by disruptions in the hair cycle, as opposed to immune alopecia like alopecia areata or localized baldness, alopecia. universal and total alopecia. Assessment and treatment could therefore be used for androgenetic alopecia, traction alopecia, female hair loss, scar alopecia, chemotherapy or radiotherapy induced alopecia, telogen effluvium, l stress-related alopecia, seasonal alopecia, age-related alopecia and micro-inflammatory alopecia.

Understanding temporary or permanent substantial hair lossHave

“Natural hair loss can be estimated, on average, at a few hundred hairs per day for a normal physiological state”the company wrote in its patent filing. “This process of constant physical renewal undergoes a natural modification during aging: the hair becomes thinner and its cycles shorter. Various causes can, however, lead to significant hair loss, whether temporary or permanent.L’Oréal wrote in its patent filing.


the anagen phaseor growth phase, the hair follicle grows back the hairs which will continue to grow until they are cut or reach the end of their lifespan. This is then followed by the catagen phaseOr transitional phase where the hair follicles shrink, the hair separates from the bottom of the hair follicle, and hair growth slows down. Then is the telegonal phaseOr resting phase where hair growth stops and hair loss begins at the end of this cycle. This is then followed by the neogenic phaseOr regeneration phase which returns to the growth phase and sees the growth of hair.

As L’Oréal explains: “The anagen phase, which is the active or growth phase during which the hair lengthens, lasts for several years. The very short catagen phase lasts a few weeks. The telogen phase or rest phase lasts a few months. At the end of this rest period, the strands of hair fall out and another cycle begins. The hair is thus in perpetual renewal and, of the approximately 150,000 locks that make up hair, around 10% are at rest and will be replaced in the coming months.Have

In common alopecia conditions, L’Oréal has stated that there are disturbances in the anagen or growth phase of the hair cycle, with a shortening of this phase; progressive thinning of the lock of hair; and a decrease in the amount of hair thereof. “A progressive miniaturization of the bulbs takes place, in conjunction with the isolation of these bulbs by progressive thickening of the collagen matrix of the external connective sheath. Revascularization around the hair follicle is thus made more difficult cycle after cycle. The hair regresses and becomes miniaturized until it is nothing more than an unpigmented down, and this phenomenon leads to a gradual thinning of the hair.Have

Overall, this type of hair loss tends to affect very specific areas that typically differ between men and women, L’Oréal said, with hair loss from the temporal or frontal region in men and diffuse crown alopecia in women. In some cases, these men and women are genetically predisposed to hair loss, but in other cases, hair loss can be a seasonal occurrence or accentuated by hormonal imbalance, physiological stress, or malnutrition.

“In general, any factor influencing these processes, namely the acceleration of the frequency of cycles, the progressive miniaturization of the bulbs, the progressive thickening of the perifollicular collagen matrix, the thickening of the external conjunctive sheath, and the blood supply. , will have an effect on the growth of hair follicles ”, L’Oréal wrote.

Identify “new biomarkers” in male hair lossHave

It was therefore important, according to the company, to find “New biological pathways” and “New biomarkers”To detect an alopecic state of the scalp, in particular before visible, to be able to reduce and / or slow down hair loss. Specifically, L’Oréal indicated that there was a “Considerable need”for this in androgenetic alopecia – male and female hair loss that has occurred very characteristically in well-defined patterns. Targeting this common form of alopecia, especially in men, he said, was the goal of these inventions.

The beauty major said she discovered that the expression of specific genes identified, involved in the intercellular junctions of the cells of the squama and / or the hair follicle, such as keratinocytes and fibroblasts, was decreased in the area where the male or female – hair loss was progressing. Measuring the expression of these genes in these areas of the scalp therefore allowed for prognosis and / or diagnosis in a subject, he said.

The expression of these genes could then also be measured after a treatment designed to either induce and stimulate hair growth, or slow hair loss, to measure the effectiveness, obtained by the inclusion of modulators or active compounds in topicals.

Demonstrate the effectiveness of topical, oral and physical treatments against hair lossHave

These measures, L’Oréal said, could be taken by taking a scalp biopsy or biopsy of one or more of the hair follicles and compared to control measures to check “statistically significant” differences in gene expression. A treatment could be considered effective, according to the company, if the expression of a specific identified gene was increased after treatment, compared to before treatment and compared to a level of control. Comparing more than one gene expression was better when testing a product’s effectiveness on androgenetic alopecia, he said.

“A treatment will be considered to have no effect if the levels of expression of the gene chosen, before and after treatment, are substantially identical, or if the differences observed are not significant. L’Oréal wrote.

Beyond topicals, these tests could also be used to measure the effectiveness of oral and physical treatments if needed, the company said. It was also possible to “Evaluate the effectiveness of the combination of several treatments” – assess which combinations best restored gene expression levels of one or more of the identified genes, he said.

New treatments and combinations versus efficacy of existing productsHave

L’Oréal said its inventions could be used to shape future innovations or qualify the effectiveness of existing products and treatments.

“In this way, combinations of treatments likely to be particularly effective, synergistic or complementary can also be considered”, it said.

Source: WIPO International Patent No. WO / 2022/003041Have
Filed on: June 30, 2021. Posted: January 6, 2022.
Title: “Molecular signature of a common alopecic state, associated with cell junctions”Have
Authors: L’Oréal – Y. Mahe, K. Bakkar and E. Bou Samra